Education
About Us
Working with TipRanks
Follow Us
Citius Pharmaceuticals (CTXR)
NASDAQ:CTXR
Total Valuation
Citius Pharmaceuticals has a market cap or net worth of $15.37M. The enterprise value is $5.83M.
Market Cap$15.37M
Enterprise Value$5.83M
Share Statistics
Citius Pharmaceuticals has 20,762,917 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding20,762,917
Owned by Insiders2.36%
Owned by Institutions0.03%
Financial Efficiency
Citius Pharmaceuticals’s return on equity (ROE) is -0.55 and return on invested capital (ROIC) is -44.69%.
Return on Equity (ROE)-0.55
Return on Assets (ROA)-0.29
Return on Invested Capital (ROIC)-44.69%
Return on Capital Employed (ROCE)-0.45
Revenue Per Employee0.00
Profits Per Employee-1.73M
Employee Count23
Asset Turnover0.00
Inventory Turnover<0.01
Valuation Ratios
The current PE Ratio of Citius Pharmaceuticals is ―. Citius Pharmaceuticals’s PEG ratio is 0.00845.
PE Ratio―
PS Ratio0.00
PB Ratio0.20
Price to Fair Value0.20
Price to FCF-0.52
Price to Operating Cash Flow-0.50
PEG Ratio0.00845
Income Statement
In the last 12 months, Citius Pharmaceuticals had revenue of 0.00 and earned -37.43M in profits. Earnings per share was -3.38.
Revenue0.00
Gross Profit-214.25K
Operating Income-38.53M
Pretax Income-38.68M
Net Income-37.43M
EBITDA-38.20M
Earnings Per Share (EPS)-3.38
Cash Flow
In the last 12 months, operating cash flow was -26.55M and capital expenditures -4.00, giving a free cash flow of -26.55M billion.
Operating Cash Flow-26.55M
Free Cash Flow-26.55M
Free Cash Flow per Share-1.28
Dividends & Yields
Citius Pharmaceuticals pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta2.31
52-Week Price Change-72.49%
50-Day Moving Average1.00
200-Day Moving Average1.16
Relative Strength Index (RSI)32.69
Average Volume (3m)1.16M
Important Dates
Citius Pharmaceuticals upcoming earnings date is Feb 6, 2026, Before Open (Confirmed).
Last Earnings DateDec 23, 2025
Next Earnings DateFeb 6, 2026
Ex-Dividend Date―
Financial Position
Citius Pharmaceuticals as a current ratio of 0.62, with Debt / Equity ratio of 2.68%
Current Ratio0.62
Quick Ratio0.13
Debt to Market Cap0.06
Net Debt to EBITDA0.09
Interest Coverage Ratio-143.87
Taxes
In the past 12 months, Citius Pharmaceuticals has paid 1.06M in taxes.
Income Tax1.06M
Effective Tax Rate-0.03
Enterprise Valuation
Citius Pharmaceuticals EV to EBITDA ratio is -0.27, with an EV/FCF ratio of -0.39.
EV to Sales0.00
EV to EBITDA-0.27
EV to Free Cash Flow-0.39
EV to Operating Cash Flow-0.39
Balance Sheet
Citius Pharmaceuticals has $4.25M in cash and marketable securities with $1.81M in debt, giving a net cash position of $2.44M billion.
Cash & Marketable Securities$4.25M
Total Debt$1.81M
Net Cash$2.44M
Net Cash Per Share$0.12
Tangible Book Value Per Share-$2.22
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
Gross Margin0.00%
Operating Margin0.00%
Pretax Margin0.00%
Net Profit Margin0.00%
EBITDA Margin0.00%
EBIT Margin0.00%
Analyst Forecast
The average price target for Citius Pharmaceuticals is ―, which is 11.43% higher than the current price. The consensus rating is ―
Price Target―
Price Target Upside―
Analyst Consensus―
Analyst Count0
Revenue Growth Forecast―
EPS Growth Forecast18.73%